RenovoRx (RNXT) Stock Forecast & Price Target

RenovoRx is benefiting from a dual-track story of clinical de-risking and early commercial traction, with the DMC recommending continuation of the Phase III TIGeR-PaC trial after the August 2025 second interim review and positive first interim results previously reported in March 2023. Revenue momentum is also accelerating, as Q2 fiscal 2026 sales rose 115% year over year to $0.9 million and Q1 grew 186% to $0.6 million, while active commercial cancer centers expanded from 5 in September 2025 to 21 currently, with 36 expected by the end of 2026. Its $12 million cash balance, no debt, and recent $10 million equity raise provide runway to scale RenovoCath commercialization and pursue a market opportunity described as roughly a billion dollars, supporting the bullish fundamental outlook.

RenovoRx is exposed to multiple fundamental risks that weaken the investment case, including balance sheet and liquidity pressure, the possibility that its product candidates fail to show adequate safety and efficacy, and the risk of not securing regulatory approvals. Its clinical-stage status also means commercial execution is unproven, while reimbursement uncertainty and competition could further limit adoption even if development progress continues. In addition, changing macroeconomic conditions, weak biotech investor sentiment, and shifting consumer or government healthcare priorities could constrain financing and market support, leaving the company highly vulnerable to setbacks.